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Key Points  Ruxolitinib showed no significant improvement for attainment of either CR or PR over BAT 
within the first year of therapy in high-risk ET  Ruxolitinib significantly improved some disease-related symptoms but rates of thrombosis, 
hemorrhage or transformation were not different 
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Abstract  
Treatments for high-risk essential thrombocythemia (ET) address thrombocytosis, disease-related 
symptoms, as well as risks of thrombosis, hemorrhage, transformation to myelofibrosis and 
leukemia. Patients resistant/intolerant to hydroxycarbamide (HC) have a poor outlook.  MAJIC 
(ISRCTN61925716) is a randomized phase II trial of ruxolitinib (JAK1/2 inhibitor) vs Best Available 
Therapy (BAT) in ET and polycythemia vera (PV) patients resistant or intolerant to HC. Here findings 
of MAJIC-ET are reported, where the modified intention-to-treat population included 58 & 52 
patients randomized to receive ruxolitinib or BAT respectively. There was no evidence of 
improvement in complete response within 1 year reported in 27 (46.6%) patients treated with 
ruxolitinib vs 23 (44.2%) with BAT (P=.40). At 2 years rates of thrombosis, hemorrhage and 
transformation were not significantly different, however between ruxolitinib and BAT. S some 
disease-related symptoms improved in patients receiving ruxolitinib, more so thanrelative to BAT. 
Molecular responses were uncommon; however there were two complete molecular responses 
(CMR) and one partial molecular response (PMR) in CALR positive ruxolitinib-treated patients. 
Transformation to myelofibrosis occurred in one CMR patient, presumably due to the emergence of 
a different clone raising questions about the relevance of CMR in ET patients. Grade 3&4 anemia 
occurred in 19% & 0% of ruxolitinib vs 0% (both grades) BAT arm, grade 3&4 thrombocytopenia in 
5.2% & 1.7% of ruxolitinib vs 0% (both grades) of BAT treated patients. Rates of discontinuation or 
treatment switching did not differ between the two trial arms. The MAJIC-ET trial suggests that 
ruxolitinib is not superior to current second-line treatments for ET. 
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Introduction 
Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm (MPN) characterized by 
thrombocytosis. Patients are at higher risk of thrombosis and hemorrhage. They also have disease-
related symptoms which are difficult to manage with standard therapies. Therapeutic approaches 
include lowering risks of thrombosis and hemorrhage, without increasing ed risk of transformation 
into myelofibrosis (PET-MF) or acute myeloid leukemia (AML), which are also part of the natural 
history of this disorder1-3. Low-dose aspirin with hydroxycarbamide (HC) is recommended as first line 
therapy in high-risk patients to reduce both platelet count and thrombotic events, as supported by 
data from randomized trials3,4. AHowever, approximately 20% of patients with ET become intolerant 
or resistant to HC and those patients with resistance appear to be at increased risk of disease 
transformation and significantly reduced overall survival5. However, tThere is a lack ofno prospective 
trial data to guide management of ET patients who are resistant or intolerant to HC; current 
treatment options are limited, and several second-line treatment options are associated with 
increased risk of disease transformation2,3,6. 
The discovery of the Janus kinase (JAK2V617F) mutation provided the first genetic marker of the 
malignant clone in MPN7-9. and highlighted  identifying the central role of JAK/STAT activation as a 
consistent pathological finding, even in those patients without the JAK2V617F mutation 10. There is 
evidence that in ET JAK2 activation is associated with platelet and leukocyte activation, and risk of 
thrombosis, especially venous events11. High JAK2V617F mutant allele burden is also associated with 
features of more advanced disease in both polycythemia vera (PV) and ET12,13. Furthermore, other 
key driver mutations associated with ET, affecting the thrombopoietin receptor MPL and calreticulin 
(CALR) also lead to increased JAK2 signaling14., highlighting the primacy of JAK2 signaling in the 
pathogenesis of ET. 
 
The JAK1/2 inhibitor, ruxolitinib, was effective in reducing spleen volume, controlling blood counts 
and improving disease symptoms in patients with MF and PV15-17.  In addition, ruxolitinib treatment 
may result in a survival advantage for patients with MF18,19. A previous non-randomized study in 39 
ET patients with ET, who were resistant or intolerant to HC, demonstrated that ruxolitinib was 
capable of lowering both platelet and white cell counts and that the most effective starting dose was 
25mg bd20. 
 
We conducted a randomized, phase II trial to evaluate the activity and safety of ruxolitinib vs Best 
Available Therapy (BAT) in two different patient populations (ET and PV) in the MAJIC trial: A 
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randomized study of best Available therapy versus JAK inhibition in patients with high-risk 
Polycythemia Vera or Essential Thrombocythaemia who are resistant or intolerant to 
HydroxyCabamide (MAJIC). The study utilized an efficient framework of a basket trial design, 
permitting the separate evaluation of two study populations. Here we present safety and efficacy 
data for the ET population of the MAJIC study, so-called MAJIC-ET.  
 
Trial design 
AWithin each arm of the MAJIC trial, an independent, parallel, open-label, randomized controlled 
trial of ruxolitinib vs BAT was implemented (Trial schema, Supplemental Figure 1). PatieŶts aged шϭ8 
with high-risk ET or PV, who met modified criteria for intolerance or resistance to HC21, 
(Supplemental Table 1), were recruited. (criteria in Supplemental Table 1).  The MAJIC-PV arm is on-
going and will be reported separately. High-risk ET was defined by standard criteria (Supplemental 
Table 2), patients were stratified by JAK2V617F status and randomized on a 1:1 ratio to receive 
either ruxolitinib (starting dose 25mg twice daily (bd) or 20mg bd, if baseline platelets were 100-
200×109/L) or BAT. Full trial inclusion and exclusion criteria are presented in (Supplemental Table 3). 
The trial was registered at www.isrctn.com (registration number ISRCTN61925716) and was 
reviewed by an independent research ethics committee. All patients entering the trial gave written 
informed consent in accordance with the Declaration of Helsinki. Trial data was analyzed by 
statisticians at the Cancer Research UK Clinical Trials Unit (University of Birmingham), UK and Quality 
of Life (QoL) analysis performed by statisticians at the Mayo Clinic, Scottsdale, Phoenix, USA. 
Ruxolitinib was provided free of charge by Novartis. All authors had access to the primary clinical 
trials data and approved the final version of the manuscript.   
Outcome measures 
The primary outcome measure was achievement of Complete Response (CR) rates as defined by 
European Leukemia Net (ELN) criteria within 1 year of treatment22. CR in ET patients was defined by 
achieving all of the following criteria: platelet ĐouŶt ч4ϬϬ×109/L; normal spleen size on imaging; 
ǁhite ďlood Đell ĐouŶt чϭϬ×109/L. Secondary outcomes included Partial Response (PR) rates per ELN 
criteria within 1 year of treatment, duration of response (both CR and PR) and overall response (i.e. 
CR&PR), toxicity profile of ruxolitinib based on National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI CTCAE) version 4, dose intensity, histological response, molecular 
response as defined by ELN; hemorrhagic and thromboembolic event rate, disease transformations, 
QoL and disease symptom burden, overall and progression free survival. The safety population 
included all patients who received at least one dose of protocol treatment. HAll hemorrhagic and 
thrombotic events were collected and centrally reviewed. QoL and symptom assessment 
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questionnaires:  included the 10-item Myeloproliferative Neoplasm Symptom Assessment Form 
Symptom Score (TSS)23, EQ-5D24 and M.D. Anderson Symptom Inventory (MDASI)25 and were 
completed by patients at baseline (pre-ior to treatment, 7 consecutive days for the MPN-10 and 
questionnaires), 2 months and 4 months post randomization and continued 4 monthly whilst on trial 
trial (once per time point per questionnaire). Overall symptom response was defined as at least a 
(average of the 7 baseline days with at least 4 of 7 days scored) at any post-baseline time point up to 
Month 12. 
Sample size justification and statistical analysis 
Sample size calculation were based upon rates obtained from preliminary phase IIdata with 
ruxolitinib in PV and ET patients20 using an one-sided normal test without continuity correction and 
unpooled variance. The CR rate for the control group was estimated to beat 30%. A clinically 
significant improvement was considered to be 20%. Thus, assuming CR rates in the control and 
treatment group were 30% and 50% respectively, 55 patients were required in each arm to detect a 
clinically significant difference of 20% with 82% statistical power at 10% level of significance. As this 
is a randomized screening trial to evaluate a direct, but nondefinitive comparison between the two 
arms, with the aim of screening for promising signal of activity in ruxolitinib, a relaxed one-sided 
significance level of 10% is utilized (Rublinstein et al 2005). Allowing for a 5% drop out rate, the total 
number required was 116 patients were required.  
 
A P<.10 was considered statistically significant for the primary outcome. For all other analyses, two-
sided tests were used and a P<.05 was considered statistically significant. The nNumber and 
proportion of patients were reported for categorical variables by treatment group and overall. 
Descriptive statistics (number of patients, mean, standard deviation (SD), median, Interquartile 
Range (IQR))  were reported for continuous variables by treatment group and overall. The number 
and proportion of patients were reported for categorical variables by treatment group and overall. 
Time-to-event outcomes were analyzed using the method of Kaplan and Meier and differences in 
survival time analyses were determined using the a Coǆ’s ŵodel with adjustment for JAK2V617F 
status as per baseline data reported by sites.  . Apart from the primary outcome, additional 
hypotheses testing were exploratory and non pre-specified. These analyses have adjusted for 
JAK2V617F status. Normal Z-tests were used to assess difference in proportions. We also fitted 
Uunivariate and multivariate logistic regression were fitted models to see assess the effect of 
baseline measures on the primary outcome, transformations and toxicity. Apart from the primary 
outcome, additional hypotheses testing were exploratory and non pre-specified. All summaries and 
statistical analyses for efficacy were primarily carried out on a modified intention to treat (mITT) 
Commented [CY1]: Please update reference. Rubinstein LV, 
Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA: Design issues of 
randomized phase II trials and a proposal for phase II screening 
trials. J Clin Oncol. 2005,23:7199-7206. 
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basis, including patients analyzed according to their randomized treatment allocation, startinged 
treatment within one year of randomization and for whichwith at least one response was available. 
Summary statistics for safety variables were based on the safety population, which included patients 
according to the treatment they actually received and who received one or more doses of 
treatment. All above statistics analyses were performed using Stata version 14.2. 
 
QoL and symptom data were analyzed for thein mITT population using SAS version 4.  Overall 
symptom response rate was compared between arms using a chi-squared test, and maximum 
percentage reduction from baseline during the first 12 months was compared between arms using a 
Wilcoxon rank-sum test.  Symptom response and percentage reduction at each post-baseline time 
point (or at most recent assessment if no symptom data at the given time point were provided) were 
similarly compared between arms using chi-squared and Wilcoxon rank-sum tests, respectively. 
Comparisons of mean scores longitudinally employed a linear mixed model for each outcome 
(starting at thefrom month 2 assessment) using all available data. In addition to a randomized arm 
covariate, each model included a continuous covariate for the baseline value of the outcome and 
used the planned month of assessment as the categorical time value with compound covariance 
structure. 
Treatment and assessments 
Ruxolitinib treatment was initiated at an appropriate dose based on baseline platelet count. BAT was 
assigned aĐĐordiŶg to phǇsiĐiaŶ’s ĐhoiĐe ďut had to ďe aŶ aĐtiǀe ageŶt, . Patients were permitted to 
change of BAT therapies was permitted with the aim of achieving a CR. CPatients were also allowed 
to receive a combination of BAT therapies but no other concurrent cytoreductive therapies werewas 
permitted.  permitted for patients on the ruxolitinib arm. No crossover of BAT patients to ruxolitinib 
was permitted. Low-dose aspirin (75mg od) was also advised for all patients unless contraindicated. 
Protocol specified dose reductions for ruxolitinib were in place for hematological, renal and hepatic 
toxicities and patients were allowed to re-escalate following a dose reduction if the toxicity had 
resolved. LThe lowest permitted dose of ruxolitinib was 5mg once- daily. HPatients were assessed 
for hematological response was assessed every 2 weeklys for 3 months,  and then every 6 weekly s 
during the first year of treatment in order to determine the primary outcome of CR during year 1 
(cut-off week 54).  Ultrasound was performed at baseline and and centrally reviewed. to confirm the 
presence or absence of splenomegaly . Patients withIf splenomegaly at was present at baseline 
required a repeat ultrasound showing a normal spleen sizeresolution was required for to be 
considered as achieving CR. RPatients continued to receive ruxolitinib continued beyond 1 year 
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moved to the BAT arm for continued follow-up. Patients who underwent transformedation to PET-
(MDS) or AML discontinued the trial but were followed up for survival. 
 
In order to achieve the secondary outcome, rate of molecular response, blood samples were taken 
from patients at baseline and 4 monthly for the duration of the trial.  Assays for JAK2V617F, CALR 
and MPL mutation allele burden was quantified using next generation sequencing as previously 
described26 An analysis of histological features is currently being performed and this data is not 
being presented as part of this manuscript. 
Results 
Patient characteristics  
116 patients were recruited in 38 UK centers within the UK between n September 2012- and 
February 2015, with a median follow up of 2.61 years (range: 0.23 – 4.12).  In total 110 were eligible 
for the mITT analysis. Comprising These consisted of 58 (52%) and 52 (48%) patients recruited toin 
the ruxolitinib and BAT arms respectively. MThe median age of patients was 64.2 years with 44 
(40%) males and 66 (60%) female patients,s enrolled, of whichoverall 28/110 (25.4%) were resistant 
to HC, 57/110 (51.8%) intolerant or 25/110 (22.7%) both. Baseline characteristics were balanced 
between the two groups (Table 1), except for the ruxolitinib arm which hadwith longer disease- 
duration and lower hemoglobin.  Overall 6 patients were excluded from the mITT analysis: 4 
withdrew before commencingwithout treatment (2 did not wish to be in the on BAT arm, one was 
ineligible,  and one had transformed to PET-MF) and 2 did not start treatment within one year from 
randomization.  All  list of all CALR indels and MPL mutations detected isare provided in 
Supplemental Table 4. 
Trial Treatment 
For patients receiving ruxolitinib, although treatment was initiated at 25mg bd in all patients the 
median dose intensity of ruxolitinib during year one was 15mg bd (Figure 1). TFor patients receiving 
BAT, the most common BAT therapies utilized at least once in the therapeutic scheme of BAT 
patients included HC in 37/52 (71.1%), anagrelide in 25/52 (48.1%) and interferon in 21/52 (40.4%) 
patients.  
Add comment about prior therapies for BAT arm 
Patient disposition at the time of the analysis (2 year follow up) is shown in Figure 2. Thirty BAT 
patients (57.7%) switched their initially assigned therapy at least once and there were a total of 86 
switches across this the BAT group.  In total, 45 patients (49.5%) discontinued treatment, with 40 
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discontinuations occurring within the first treatment year. Thirty- five patients (60.3%) receiving 
ruxolitinib and 10 patients (19.2%) receiving BAT discontinued treatment. The main reasons for 
discontinuation in the ruxolitinib arm were loss of response (11/35 (31.4%)) and transformation 
(9/35 (25.7%)). The main reasons for discontinuation in the BAT arm were transformation (3/10 
(30%]) and death (2/10 (20%)). Discontinuations and therapy switches are shown in Table 2. 
Efficacy analysis 
For patients meeting the criteria for mITT analysis the primary outcome (CR) was achieved in 27 
(46.5%) of the patients in the ruxolitinib arm vs 23 (44.2%) in the BAT arm (Unadjusted P =.40, 
adjusted for JAK2V617F status P=0.40) with a difference of proportions -2.3% between BAT and 
ruxolitinb (80% CI: -15%, 10%). PR occurred in 27 (46.5%) patients in the ruxolitinib arm and 27 
(51.9%) patients in the BAT arm (Figure 3A). The tTime to first response (CR or PR) between the two 
arms was significantly different (P=.01; Figure 3B) with BAT patients taking longer to reach this point. 
Although duration of CR appeared shorter for ruxolitinib patients, this was not statistically significant 
(Figure 3C) and there was no evidence of a difference in duration of overall response (CR and PR) 
between ruxolitinib and BAT (Figure 3D). Overall survival (OS) and progression free survival (PFS) at 1 
year were similar (OS: .98 (95%CI .86, .99) for BAT and .98 (95%CI 0.88, 0.99) for ruxolitinib patients, 
PFS: .96 (95%CI .85, .99) for BAT and .93 (95%CI .81, .97) for ruxolitinib patients). In multivariate 
analyses performed to assess baseline factors influencing CR (modelled for: treatment received, HC 
resistance/intolerance, white cell count, platelets, hemoglobin & JAK2/CALR status) no factor was 
shown to be significant and did not change the treatment effect (Supplemental Table 54). 
Thrombosis, hemorrhage and disease transformation 
After 2 years of follow up transformation to PET-MF occurred in 8 ruxolitinib vs. 5 BAT treated 
patients. Transformation to AML was seen in 1 patient who received ruxolitinib. Transformation free 
survival event free probability was not significantly different between the two arms (P=0.29; 
Supplemental Figure S24A). Concerning thrombosis and hemorrhage, following central review, 10 
patients (17.2%) on the ruxolitinib arm experienced 11 thrombotic events compared to 3 patients 
(5.8%) on the BAT arm experiencing 5 events. Hemorrhagic events were 1 (1.7%) vs 5 (8.9%) for 
ruxolitinib and BAT patients respectively (Table 3). Concerning the thrombosis free survivalevent 
free probability, the differences were borderline but not statistically significant (P =.09; 
Supplemental Figure S24B). Hemorrhage was less frequent for patients treated with ruxolitinib, 
however this difference was not significant (P =.14; Supplemental Figure S24C). Since all of these 
events are considered clinically relevant we performed an analysis of transformation, thrombosis 
and hemorrhage as a composite endpoint; there was no evidence of a difference (P =.35; 
Supplemental Figure S42D). Most thrombotic and hemorrhagic events occurred in patients in CR or 
Commented [CY2]: Please check. Figure on consort diagram 
appears to be higher. 
Commented [EG3]: Both numbers are correct. However, 3 out 
of 10 patients that discontinued withdrew consent as well and are 
therefore recorded in the discontinuation category. 
Commented [CY4]: Are those rates adjusted for JAK2?  
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PR (Supplemental Figure S32). In a multivariate analysis of factors influencing transformation to PET-
MF, this event only occurred in patients with baseline WBC <10×109/L (Supplemental Table 65). 
Molecular responses (MR) 
The mean baseline allele burdens for JAK2V617F, CALR or MPL mutation positive patients are 
displayed in Table 1. At 12 months, or the last available sample during year 1, the overall mean allele 
burden had not changed significantly for any mutation in either treatment arm. However, 1 
complete molecular response (CMR) and 1 partial molecular response (PMR) per ELN criteria were 
seen for JAK2V617F positive patients on the ruxolitinib arm and 2 CMRs and 1 PMR for CALR positive 
patients on ruxolitinib compared to 0 CMRs/PMRs for patients with these mutations receiving BAT. A 
JAK2V617F positive patient who achieved a PMR on ruxolitinib also had resolution of a cytogenetic 
abnormality at one year. There was no pattern of MR or progression with complete or partial 
hematological response or transformation, but 1 CALR positive patient who transformed to PET-MF 
had a CMR. 
Impact on ET Related Disease Symptom Burden 
Among 110 patients in the mITT cohort, 85 completed the baseline and at least one post-baseline 
questionnaire (ruxolitinib N=47, BAT N=38). While overall symptom response rate during the first 12 
months did not significantly differ between arms (ruxolitinib 12/42 (29%) vs BAT 6/31 (19%), P=.37), 
maximum percentage TSS reduction at any point during the first 12 months of treatment was 
significantly greater for ruxolitinib compared to BAT (median reduction 32% vs 0%, P=.03, Figure 
35A). Symptom response was rapid in the ruxolitinib arm (8/42 (19%) at 2 months) as compared to 
BAT (1/31 (3%) at 2 months, P =.04). Longitudinally, mean TSS (P=.03) and the individual symptom of 
pruritus (P=.01) were significantly lower for ruxolitinib vs BAT (Figure 35B and 35C), with trends 
observed for improved concentration (P=.05), lower anxiety/depression (EQ5D P=.09), and higher 
ability to perform usual activities (EQ5D P=.09) on the ruxolitinib arm compared to BAT. 
Safety 
All safety analysis has been conducted on the safety population: which includes 115 patients (57 
BAT, 58 RUX). A total of 128 Grade 3/4 events occurred in 89 patients on the trial (Supplemental 
Table 64). Hematological toxicities (36/101128) and metabolism/nutrition disorders (17/101 128 – 
10 relating to hyponatremia) were the most common.  Grade 3 or 4 anemia occurred in 12/58 (21%) 
of ruxolitinib patients vs 0/57 (0%) in the BAT patients (P<.005), grade 3 or 4 thrombocytopenia in 
2/58 (3.4%) of ruxolitinib vs 0/57 (0%) of BAT patients (P=.32), and grade 3 (only) infections occurred 
in 9/58 (15.5%) of patients in the ruxolitinib arm compared to 2/57 (3.5%) (grade 3 and 4) in the BAT 
arm (P=.03). Overall 2 patients discontinued ruxolitinib for anemia; there were no discontinuations 
related to thrombocytopenia. Blood counts during the trial according to treatment arm are shown in 
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Supplemental Figure 46, demonstrating equivalent control of leucocytes and platelets but lower 
hemoglobin from week 4. An unplanned multivariate ŵodel ;ŵodelled for heŵogloďiŶ ;ш ϭϬϬg/dlͿ 
and JAK2/CALR status) demonstrated that hemoglobin (ш<100g/dl) was significant in predicting the 
occurrence of anemia or thrombocytopenia (OR=.17, 95% CI=.04, .72, P=0.01 ) (Supplemental Table 
86). 
There were 5 patient deaths in the ruxolitinib arm and 2 in the BAT arm, none were considered to be 
treatment related. The deaths in the BAT arm were due to multiple organ failure and cerebral 
hemorrhage. In the ruxolitinib arm, deaths were due to carcinomatosis combined with esophageal 
cancer, bowel infarction due to adhesions, acute left ventricular failure, ischemic cardiomyopathy 
and sepsis combined with pancreatic cancer.  
Discussion  
ET is often regarded as the most indolent of the Philadelphia negative MPNs. Treatments for high-
risk ET offer improvements in blood counts and reduction in risk of thrombosis and hemorrhage with 
a lack of certainty regarding effects upon transformation to PET-MF and AML2,3. Criteria for 
resistance or intolerance to standard therapy with HC were originally developed to guide clinicians 
when to initiate second-line therapies; however, there is now evidence that HC resistant patients 
have a poor outlook27. In addition, disease-related symptom burden is increasingly recognized as an 
important disease feature, causing significant morbidity with few effective treatments2-4. In previous 
studies patients with MF displayed a  survival benefit with ruxolitinib, which also reduced spleen size 
and symptoms when compared to BAT18. In the RESPONSE study in HC resistant/intolerant patients 
with PV there was a suggestion of lower rates of thrombosis in patients receiving ruxolitinib 
compared with BAT, as well as better control of blood counts, spleen size and symptoms17. 
The MAJIC trial was designed to compare ruxolitinib with BAT in patients with HC intolerance/ 
resistance in two populations, MAJIC-ET and MAJIC-PV. There isRepresenting considerable gain in 
efficiency in terms of resources, labor and time compared to running two separate trials. Also, there 
is an added advantage of consistency as both studies are run under one protocol.  Both trial 
populations are fully recruited and here we report the findings of MAJIC-ET trial. The patients 
recruited into MAJIC-ET displayed characteristics that were well-balanced between the two arms 
with the exception of baseline hemoglobin and prior disease duration. Distribution of driver 
mutations JAK2V617F, MPL exon 10, CALR mutations were as expected. Our pPatients had a long 
disease duration (up to 31 years) and some of whom had received multiple therapy lines with up to 
nine prior therapies. Some features of advanced disease, for example splenomegaly and leukocytosis 
were present at baseline however transformation to PET-MF was excluded at trial entry. Diagnostic 
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criteria have been controversial in ET and those in use at trial centres were as follows …. British 
Committee for Standards in Haematology (BCSH n=18); WHO 2001/2008 (n=11) and both combined 
(n=3). The BCSH and WHO criteria were recently shown to perform equally well. [REF)  
Something here about standard second line therapies.Usual therapy choice in the second-line 
setting for ET would be anagrelide or iŶterferoŶ, hoǁeǀer iŶ order to perforŵ a ͞real-life 
ĐoŵparisoŶ͟ we allowed investigator choice overall  the majority, 79% (41/52), of BAT patients 
received one or both agents before or during the study. On-study BAT included in addition busulfan 
32P and remaining on HU several international guidelines recommend busulfan or 32P for older 
patients. Some features of advanced disease, for example splenomegaly and leukocytosis were 
present at baseline however transformation to PET-MF was excluded at trial entry. Diagnostic 
Đriteria iŶ use at trial ĐeŶtres ǁere as folloǁs …. 
 
In MAJIC-ET numbers pProportion of patients reaching CR within one year were not differentsimilar: 
27 (46.5%) in the ruxolitinib arm vs 23 (44.2%) for BAT, with similar data for the achievement of PR 
rates. Time to any first response (CR or PR) was significantly faster for patients treated with 
ruxolitinib (P=.012). This finding isA particularly interesting finding, as patients in CR who were 
randomized to receive ruxolitinib had to change therapy and potentially lost any pre-existing 
response yet managed to attain CR faster than BAT patients who may not have changed therapy and 
thus only needinged to maintain their response. In addition, BAT patients were also allowed to 
combine or to switch therapies and frequently did so. Importantly however the duration of CR 
appeared shorter for ruxolitinib patients with a marginally significant value, while the duration of 
overall response (CR and PR) was not different between both arms. We confirm that HC 
resistant/intolerant ET patients have a high-risk of thrombosis, hemorrhage and transformation to 
PET-MF; event rates here being higher than reported in the non-resistant/intolerant,  population for 
example the e.g. PT-1 or ANAHYDRET studies28,29. Transformation for may have been more likely for 
ruxolitinib treated patients due to the higher prevalence of anemia and longer disease duration for 
this cohort. However, overall thrombosis, hemorrhage or transformationthese events when  
considered separately or together as a composite endpoint were not statistically different between 
the ruxolitinib and BAT. Furthermore, in a post hoc unplanned analysis for factor influencing 
transformation to PET-MF, only a leucocyte count <10x109/L was significant. Several studies have 
reported that post-randomization exclusions of patients in randomized trials may affect trial results 
(Montedori et al 2011), with some raising concerns that the investigated therapy might be favored 
(Tierney et al, 2005; Melander et al 2003). However, in the MAJIC-ET trial, if we were to conduct a 
pure intention-to-treat (ITT) analysis, this would require imputation of missing response data for 6 
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BAT patients. Missing data imputation may bias estimates of treatment effects.  A commonly used 
technique is nonresponder imputation (EMA, 2010), which will attribute all 6 BAT patients as not 
achieving CR within a year. This will result in a less conservative ITT analysis of 23/58 CR (BAT) vs 
27/58 CR (RUX), with p-value of .22 compared to the mITT analysis (p=.4). Our primary findings of no 
evidence of superiority of Ruxolitinib were however consistent using either mITT or ITT analysis. 
Molecular responses were uncommon in the first year of the trial, as has been described 
previously20. However, ruxolitinib was associated with two CMR and one PMR in a CALR positive 
patient that has not previously been reported. Given the low overall number of molecular responses 
it is has not been possible to correlate with other clinical endpoints. Transformation to PET-MF in 
one CALR positive patient, who achieved a CMR, presumably occurred due to the emergence of a 
different clone, consistent with patients reported with JAK2V617F positive chronic phase developing 
JAK2V617F negative AML30, and raises questions about the relevance and value of CMR in patients 
with ET.  
Patterns of adverse events with ruxolitinib were similar to those already reported, most prevalent 
events related to hematological, nutritional and metabolic events. Infections were also more 
common with ruxolitinib therapy. There was no suggestion of imbalance between the two arms of 
MAJIC-ET for non-melanoma skin cancer as was previously noted in the RESPONSE trial17. Treatment 
discontinuation occurred more frequently for patients treated with ruxolitinib, with 35 patients 
discontinuing treatment compared to 9 discontinuations in the BAT arm. However, 30 BAT patients 
switched their initially assigned BAT treatment for various reasons, which indicates a similar rate of 
treatment ineffectiveness or intolerance. For the first time, we show baseline anemia predicted for 
treatment emergent anemia and thrombocytopenia. 
Patients with ET have a high burden of symptoms, which have been consistently reported to affect 
their quality of life31. The symptom response rate, defined as a 50% reduction in TSS, during the first 
12 months did not significantly differ between the two arms. However, maximum percentage TSS 
reduction during the first 12 months of treatment was significantly greater for ruxolitinib compared 
to BAT and was more rapid in the ruxolitinib arm. Longitudinally, mean TSS and individual symptom 
of pruritus were significantly lower for ruxolitinib, with trends observed for improved concentration, 
lower anxiety/depression and higher ability to perform usual activities for ruxolitinib arm compared 
to BAT indicating a novel and important benefit to ET patients of ruxolitinib therapy. 
Limitations of our trial include that the trial refleĐted ͞real life praĐtiĐe͟ iŶ use of diagŶostiĐ Đriteria 
and selection of BAT therapies. The majority of our centers used ǆǆǆǆǆ diagŶostiĐ Đriteria ǁhiĐh….. 
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Guidelines recommend anagrelide as second line therapy for ET, many of our patients had already 
been treated with this drug (25 received anagrelide, 7 interferon and 7 both agents) before study 
entry. Regarding the choice of BAT therapy 235 patients received anagrelide, 1920 interferon, 54 
had both drugs as BAT therapy. both tThe use of HC as a BAT and frequent switching of BAT 
therapies which occurred in almost two thirds of the BAT arm. However these factors also reflect 
real-life constraints and the limited treatment options for ET patients with resistance/intolerance to 
HC and highlight the need for newer therapies in this field. 
In conclusion, the MAJIC-ET trial suggests there is insufficient evidence that ruxolitinib has improved 
treatment efficacy compared to BAT for most clinically relevant events. Some symptom responses 
were superior with ruxolitinib therapy but there was no difference in this study for control of blood 
counts or other relevant endpoints such as transformation, thrombosis or hemorrhage.  
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Figure 1. Dose of Ruxolitinib received throughout study 
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Figure 2. Trial consort diagram at second safety analysis 
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Figure 3. Analyses of response 
Figure 4A. Transformation event free probabilitysurvival by treatment arm 
Figure 53. Changes in ET Related Symptom Burden during year 1 of the MAJIC-ET trial 
Figure 53A. 
 
Figure 53B.  
 
Figure 53C. 
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Figure 6. Hematological variables during the first year of the MAJIC-ET trial 
Figure 1 
Figure illustrating doses of ruxolitinib throughout the MAJIC-ET trial 
 
Figure 2 
Trial consort diagram including data to second safety analysis 
Figure 3A 
Figure 4B 
Changes in ET Related Symptom Burden during year 1 of the MAJIC-ET trial 
Figure 53A shows a waterfall plot of maximum percentage change in the MPN SAF TSS score, dotted 
line indicates 50% reduction in TSS 
Figure 53B shows mean MPN-SAF TSS throughout the first year of the trial there was a consistent 
trend for reduction for ruxolitinib 
Figure 53C shows the mean MPN-SAF score for itching during the first 12 months of the MAJIC-ET 
trial 
 
Figure 6 
Tables   
Table 1. Baseline characteristics by treatment  
 Best Available Therapy (52) Ruxolitinib (58) Overall  (110) 
Age 
Mean (sd) [Range] 65.6 (13.5) [37.2, 85.4] 62.9 (12.3)  [34.5, 90.5] 64.2 (12.9)[34.5, 90.5] 
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Gender, n (%) 
Female 30 (57.7) 36 (62.1) 66 (60.0) 
Male 22 (42.3) 22 (37.9) 44 (40.0) 
Mutation status, n (%) 
JAK2V617F Positive 26 (50.0) 28 (48.3) 54 (49.1) 
CALR mutation positive 147 (32.726.9) 20 (34.5) 347 (33.630.9) 
MPL mutation positive 3 (5.8) 2 3 (3.45.2) 5  6  (4.65.5) 
Triple negative 6 7 (11.513.5) 8 6(13.810.3) 14 13(12.711.8) 
Not run 2 (3.8) 1 (1.7) 3 (2.7) 
HC Resistant or Intolerant*,  n (%) 
Resistant 25 (48.1) 28 (48.3) 53 (48.2) 
Intolerant 27 (51.9) 30 (51.7) 57 (51.8) 
Time from diagnosis to randomization, years** 
Mean (sd) [Range] 6.9 (5.8) [.4, 23.6] 10.4 (6.7) [.7, 31.2] 8.8 (6.5)[.4, 31.2] 
Hemoglobin, g/L** 
Mean (sd)  [Range] 126 (17) [90.0, 160.0] 119 (17) [87.0, 152.0] 122 (17) [87.0, 160.0] 
Platelet count x 10 9 / L 
Mean (sd) [Range] 573.0 (227.1) [166.0, 1406.0] 545.4 (215.3) [89.0, 1139.0] 558.4 (220.4) [89.0, 1406.0] 
WBC count x 10 9 / L 
Mean (sd) [Range] 6.8 ( 2.7) [2.8, 15.2] 7.5 ( 4.8) [1.7, 29.8] 7.2 ( 3.9) [1.7, 29.8] 
Hematocrit 
Mean (sd) [Range] 0.4 ( 0.1) [0.3, 0.5] 0.4 ( 0.1) [0.3, 0.5] 0.4 ( 0.1) [0.3, 0.5] 
Spleen size 
Enlarged 9 14 23 
Normal 38 37 75 
Splenectomy 2 3 5 
Missing 3 4 7 
Number of Previous Therapies, n (%) 
1 15(28.8) 14 (24.1) 28 (26.4) 
2 20 (38.5) 24 (41.4) 44 (40.0) 
3 8 (15.4) 12 (20.7) 20 (18.2) 
4 5 (9.6) 5 (8.6) 10 (9.1) 
5 2 (3.8) 2 (3.4) 4 (3.6) 
6 2 (3.8) 0 (.0) 2 (1.8) 
9 0 (.0) 1 (1.7) 1 (.9) 
Total number of previous therapies by treatment, number (%) ¥ 
Hydroxycarbamide 59 (52.2) 70 (58.8) 129 (55.6) 
Anagrelide 29 (25.7) 31 (26.1) 60 (25.9) 
Interferon 7 ( 6.2) 11 (9.2) 18 (7.8) 
Pegylated  Interferon 2 (1.8) 2 (1.7) 4 (1.7) 
Busulfan 8 (7.1) 1 (.8) 9 (3.9) 
32P 3 (2.7) 1 (.8) 4 (1.7) 
Pipobroman 1 (.9) 1 (.8) 2 (.9) 
Fedratinib 1 (.9) 1 (.8) 2 (.9) 
Vorinostat 2 (1.8) 0 (.0) 2 (.9) 
Thalidomide 0 (.0) 1 (.8) 1 (.4) 
Missing 1 (.9) 0 (.0) 1 (.4) 
HC Hydroxycarbamide; WBC white blood cell; *25 patients were both resistant and intolerant. These patients have been 
included as resistant; **Time from diagnosis to randomization and baseline hemoglobin were different between the two 
treatment arms; ¥ Patients were allowed to receive multiple therapies, therefore total number of therapies in each 
category might exceed number of patients 
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Table 2. Overview of assigned therapy switches and discontinuations per treatment arm  
 
Ruxolitinib BAT Total 
Assigned therapy switches 
Patients that switched BAT therapy at least once N/A 30 30 
Total number of times BAT therapy was switched N/A 86 86 
Discontinuations 
Transformation 9 3 12 
Loss of response 11 0 11 
Lack of efficacy 5 1 6 
Toxicity 
Anemia 2 0 2 
Other 3 1 4 
Other 3 3 6 
Death 1 2 3 
Withdrawal of consent 1 0 1 
Total 35 10 45 
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Table 3. Thrombotic and hemorrhagic events  
  
  
BAT Ruxolitinib 
Total Grade 
1&2 
Grade 
3&4 
Grade 
5 
Grade 
1&2 
Grade  
3&4 
Grade 5 
Hemorrhagic events 
Hematuria 1 0 0 0 0 0 1 
Intracranial hemorrhage 0 0 1 0 0 0 1 
Oral hemorrhage 1 0 0 1 0 0 2 
Rectal hemorrhage 1 1 0 0 0 0 2 
Total 3 1 1 1 0 0 6 
ThroŵďotiĐ eveŶts ᶧ 
Chest pain - cardiac 0 1 0 0 0 0 1 
Myocardial infarction 0 0 0 0 2 0 2 
Cerebrovascular ischemia 1 0 0 0 0 0 1 
Retinal vascular disorder 1 0 0 1 0 0 2 
Thromboembolic 
events 
PE 0 0 0 0 3* 0 3 
DVT 0 0 0 1 1 0 2 
Calf vein DVT 0 0 0 0 1 0 1 
Transient ischemic attacks 2 0 0 2 0 0 4 
Total 4 1 0 4 7 0 16 
PE Pulmonary Embolism; DVT Deep Vein Thrombosis 
ᶧ The death of a ruxolitinib treated patient due to ischemic cardiomyopathy occurred more than 30 
days past treatment and is therefore not recorded as an event 
* 1 patient experienced PE and DVT at the same time, but was counted in the PE category 
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*A sepsis and pancreatic cancer related death of 1 ruxolotinib patient occurred more than 30 days 
